Since its founding in 2014, a16z Bio+ Health has raised four funds of nearly $3 billion each, including a $1.5 billion fund ...

Health-care companies rose amid sales growth optimism. Drug-store chain CVS Health said it has seen complaints of strong push back from patients on its pharmacy-benefit manager's move to favor Novo ...

By Bhanvi Satija and Christy Santhosh (Reuters) -Talks with the Trump administration about lowering U.S. drug prices have so ...

"Under the circumstances—including the lack of evidence regarding harm that Nike will suffer, the brevity of the stay, and ...

Shares of Eli Lilly & Co. rallied 4.33% to $807.19 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.55% to 6,038.81 and the ...

Eli Lilly (LLY) revealed a new stipulation regarding its business dealings with telehealth companies Ro and LifeMD (LFMD), ...

BioSpace did a deep dive into executive pay, examining the highest compensation packages, pay ratios and golden ...

FacebookTweetPin Energy, healthcare, and chip stocks are carrying the market today. The S&P 500 Energy sector is up 2.16%, ...

The newly formed Indianapolis Local Education Alliance is scheduled to host its first public meeting later this month. The alliance is a city-led group charged by the Indiana ...

The Scorpion Therapeutics spinoff sold rights for two EGFR inhibitors to Pierre Fabre Laboratories and is hoping to become a clinical-stage firm by 2026.

In JAMA, the FDA's Makary and Prasad said they will focus on modernizing review processes and lowering drug costs but don't outright mention precision medicine.

Five months after selling a cancer drug to Lilly for up to $2.5 billion, Scorpion has debuted a successor company led by its former management team to chase “previously inaccessible” drug targets.